公开(公告)号：US11787842B2

公开(公告)日：2023-10-17

申请号：US17236409

申请日：2021-04-21

Applicant: International AIDS Vaccine Initiative, Inc.

Inventor： Ravi Anantha ,  Nathalie Cadieux ,  Thomas G. Evans ,  Michele Stone ,  Barry Walker

IPC: C07K14/35 ,  A61K39/04 ,  A61K39/00

CPC classification number: C07K14/35 ,  A61K39/04 ,  A61K2039/523 ,  A61K2039/545 ,  A61K2039/55561 ,  A61K2039/55572 ,  A61K2039/70 ,  C07K2319/00

Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.

公开(公告)号：US20230293440A1

公开(公告)日：2023-09-21

申请号：US18180801

申请日：2023-03-08

Applicant: ACCESS TO ADVANCED HEALTH INSTITUTE

Inventor： Christopher B. FOX ,  Thomas VEDVICK ,  Lucien BARNES, V ,  Ryan M. KRAMER ,  Steven G. REED

IPC: A61K9/19 ,  A61K39/00 ,  A61K39/04 ,  A61K39/39 ,  A61K47/22 ,  A61K47/26 ,  A61K47/10

CPC classification number: A61K9/19 ,  A61K39/00 ,  A61K39/04 ,  A61K39/39 ,  A61K47/22 ,  A61K47/26 ,  A61K47/10 ,  A61K2039/55572 ,  A61K2039/552 ,  A61K2039/55511

Abstract: The invention provides for thermostable lyophilized formulations, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response, and methods of use thereof. The lyophilized formulations generally comprise an antigen and/or an adjuvant, a metabolizable oil, and a cake-forming excipient.

公开(公告)号：US20230287330A1

公开(公告)日：2023-09-14

申请号：US18320834

申请日：2023-05-19

Applicant: Wisconsin Alumni Research Foundation

Inventor： Adel M. Talaat

IPC: C12N1/20 ,  C12Q1/689 ,  C07K14/195 ,  C07K14/35 ,  C12N1/36 ,  G01N33/569 ,  A61K39/04 ,  C12N15/10 ,  C12N15/113

CPC classification number: C12N1/20 ,  C12Q1/689 ,  C07K14/195 ,  C07K14/35 ,  C12N1/36 ,  G01N33/5695 ,  A61K39/04 ,  C12N15/1031 ,  C12N15/1136 ,  C12Q2600/156 ,  A61K2039/522

Abstract: Described herein is a mycobacterium mutant, comprising at least one mutation in at least one gene sequence encoding global gene regulators (GGRs) selected from the group consisting of sigH, sigL, sigE, ECF-1, and mixtures thereof, wherein the GGR gene is at least partially inactivated. Described herein also is a vaccine based on the mutant and a method of differentiating between subjects that have been infected with mycobacterium and subjects that have not been infected with mycobacterium or have been vaccinated with a mycobacterium vaccine.

公开(公告)号：US20230190877A1

公开(公告)日：2023-06-22

申请号：US18045572

申请日：2022-10-11

Applicant: Altor Bioscience, LLC

Inventor： Bai Liu ,  Peter Rhode ,  Wenxin Xu ,  Hing C. Wong

IPC: A61K38/20 ,  A61K39/395 ,  C07K16/28 ,  C07K16/32 ,  C07K14/54 ,  C07K14/715 ,  C07K19/00 ,  A61K39/04

CPC classification number: A61K38/2086 ,  A61K39/39558 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2887 ,  C07K16/32 ,  C07K14/5443 ,  C07K14/7155 ,  C07K19/00 ,  A61K39/04 ,  C07K2319/30 ,  C07K2317/732 ,  C07K14/35

Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

公开(公告)号：US11679150B2

公开(公告)日：2023-06-20

申请号：US17190182

申请日：2021-03-02

Applicant: The United States of America, as represented by the Secretary of Agriculture

Inventor： Robert E Briggs ,  Fred M Tatum

IPC: C07K14/00 ,  A61K39/102 ,  A61P31/04 ,  A61K39/04 ,  A61K39/00

CPC classification number: A61K39/102 ,  A61K39/04 ,  A61P31/04 ,  A61K2039/5256

Abstract: The present invention relates to modified Mannheimia haemolytica (M. haemolytica) lktCA gene cluster cassettes, compositions comprising such cassettes, methods of using such cassettes and compositions, and kits comprising such cassettes and compositions. Also described herein are Mycoplasma bovis (M. bovis) protective antigens, compositions comprising such antigens, methods of using such antigens and compositions, and kits comprising such antigens and compositions. Also described herein are modified M. haemolytica lktCA gene cluster cassettes engineered to express M. bovis protective antigens, compositions comprising such cassettes, methods of using such cassettes and compositions, and kits comprising such cassettes and compositions.

公开(公告)号：US11679144B2

公开(公告)日：2023-06-20

申请号：US17825959

申请日：2022-05-26

Applicant: Altor Bioscience, LLC

Inventor： Bai Liu ,  Peter Rhode ,  Wenxin Xu ,  Hing C. Wong

IPC: A61K38/20 ,  C07K16/28 ,  C07K14/54 ,  C07K14/715 ,  C07K14/35 ,  A61K39/395 ,  C07K16/32 ,  C07K19/00 ,  A61K39/04

CPC classification number: A61K38/2086 ,  A61K39/04 ,  A61K39/39558 ,  C07K14/5443 ,  C07K14/7155 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2887 ,  C07K16/32 ,  C07K19/00 ,  C07K14/35 ,  C07K2317/732 ,  C07K2319/30 ,  A61K39/39558 ,  A61K2300/00 ,  A61K38/2086 ,  A61K2300/00

Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

公开(公告)号：US11666648B2

公开(公告)日：2023-06-06

申请号：US17268789

申请日：2019-08-15

Applicant: Albert Einstein College of Medicine

Inventor： William R. Jacobs, Jr. ,  Sangeeta Tiwari

IPC: A61K39/04 ,  A61P37/04 ,  C12N15/52 ,  C12Q1/6897 ,  A61K39/00

CPC classification number: A61K39/04 ,  A61P37/04 ,  C12N15/52 ,  C12Q1/6897 ,  A61K2039/522

Abstract: Provided are attenuated strains of M. tuberculosis and M. bovis BCG which are double auxotrophic mutants with genes knocked out in the biosynthetic pathways for arginine and methionine, and compositions and methods of use thereof.

公开(公告)号：US20230149525A1

公开(公告)日：2023-05-18

申请号：US18154177

申请日：2023-01-13

Applicant: IMMODULON THERAPEUTICS LIMITED

Inventor： CHARLES AKLE ,  SATVINDER MUDAN ,  JOHN GRANGE

IPC: A61K39/04 ,  A61K35/74 ,  A61K45/06 ,  A61N5/10

CPC classification number: A61K39/04 ,  A61K35/74 ,  A61K45/06 ,  A61N5/1001 ,  A61K2039/521

Abstract: The present invention provides an immunomodulator for use in the treatment and/or control of a neoplastic disease in a patient intended to undergo immunogenic cell death therapy simultaneously, separately or sequentially with administration of the immunomodulator. The therapy can be selected from microwave irradiation, targeted radiotherapy, embolisation, cryotherapy, ultrasound, high intensity focused ultrasound, cyberknife, hyperthermia, radiofrequency ablation, cryoablation, electrotome heating, hot water injection, alcohol injection, embolization, radiation exposure, photodynamic therapy, laser beam irradiation, and combinations thereof.

公开(公告)号：US11642405B2

公开(公告)日：2023-05-09

申请号：US16624722

申请日：2018-06-19

Applicant: Washington University

Inventor： Shabaana Abdul Khader ,  Mushtaq Ahmed ,  Ali Fattom ,  Douglas Smith ,  Tarek Hamouda

IPC: A61K39/04 ,  G01N33/50 ,  A61K39/00

CPC classification number: A61K39/04 ,  G01N33/505 ,  A61K2039/5154 ,  A61K2039/543 ,  A61K2039/55566

Abstract: The present disclosure relates to compositions and methods for inducing an immune response to a composition of the invention in a subject. Additionally, the present disclosure generally relates to methods for screening for immune response to a composition of the invention.

公开(公告)号：US20190240310A1

公开(公告)日：2019-08-08

申请号：US16319812

申请日：2017-07-31

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Marcus A. HORWITZ ,  Qingmei JIA

IPC: A61K39/114 ,  A61K39/235 ,  A61K39/02 ,  A61K39/07 ,  A61K9/00 ,  A61P37/04 ,  A61K39/04 ,  C07K14/32 ,  C07K14/20 ,  C07K14/36

CPC classification number: A61K39/114 ,  A61K9/0019 ,  A61K9/0043 ,  A61K9/0053 ,  A61K39/02 ,  A61K39/0291 ,  A61K39/04 ,  A61K39/07 ,  A61K39/235 ,  A61K2039/522 ,  A61K2039/523 ,  A61P37/04 ,  C07K14/195 ,  C07K14/20 ,  C07K14/32 ,  C07K14/36 ,  C12N1/20 ,  C12N1/36 ,  Y02A50/405 ,  Y02A50/407

Abstract: A method of immunizing a susceptible host against a pathogen comprising administering to the host a vaccine that comprises an attenuated recombinant live vaccine strain lacking a polynucleotide encoding CapB (LVS ΔcapB), wherein the LVS ΔcapB expresses an antigen of at least one pathogen from Table 1; or administering to the host a vaccine that comprises an attenuated Listeria monocytogenes expressing the antigen of the pathogen from Table 1; or administering to the host a prime vaccine and a heterologous booster vaccine where the prime vaccine comprises an attenuated recombinant live vaccine strain lacking a polynucleotide encoding CapB (LVS ΔcapB), wherein the LVS ΔcapB expresses an antigen of at least one pathogen from Table 1 and the heterologous booster vaccine comprises an attenuated Listeria monocytogenes expressing the antigen of the pathogen from Table 1.